Publication
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugGefitinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR D761Ycivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 17085664
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR E746_A750del1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4206In lung adenocarcinoma patients with EGFR E746_A750del mutation (n=2), EGFR E746_A750del was associated with improved response to erlotinib treatment. The patients were treated with erlotinib monother… (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC | civic |
| EGFR E746_T751delinsA1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4222In a lung adenocarcinoma patient with EGFR E746_T751>A mutation EGFR E746_A751>A was associated with improved response to erlotinib treatment. The patient was treated with erlotinib monotherapy and ac… (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC | civic |
| EGFR T790M1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | submitted | EID3806In a lung adenocarcinoma patient with EGFR E746_A751>A (a known erlotinib sensitizing mutation) and EGFR T790M co-mutation treated with erlotinib monotherapy, EGFR T790M was associated with disease pr… (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC | civic |
| EGFR D761Y1 | ||||||||
| Erlotinib + GefitinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID1763D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a … (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC | civic |